VIRAGEN INC

Viragen Inc, CIK 353482, classified under Biological Products (No Diagnostic Substances) and tied to SIC 2836, develops therapeutic and vaccine solutions grounded in recombinant DNA and bioreactor systems to serve research institutions and niche pharmaceutical partners pursuing novel immunotherapies. Its portfolio centers on viral vector platforms and peptide analogs designed to bolster immune response in oncology and infectious disease programs, while its manufacturing support services help smaller biotechs scale preclinical proof-of-concept work. The company confronts price and reimbursement pressures typical for early-stage biologics, along with the usual FDA oversight on clinical trials, biologics license applications, and facility compliance; failure to secure timely approvals or maintain accelerator-level quality controls could delay commercialization and strain liquidity. Public transparency trails the last registered disclosure, namely the Form S-1 filed December 1999, so investors should recognize the limited filing activity and the evolving regulatory landscape before wagering capital. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025